Science & Technology DeSimone awarded Lemelson-MIT Prize for innovations in polymer chemistry
| DeSimone awarded Lemelson-MIT Prize for innovations in polymer chemistry |
|
| Wednesday, June 25, 2008 | |
  To view a short video profile of Joseph DeSimone and listen to podcasts of him talking about his work, go to: http://web.mit.edu/invent/a-winners/a-desimone.htmlCAMBRIDGE, Mass. (June 25, 2008) – For Dr. Joseph M. DeSimone, the interface between seemingly disparate fields and concepts offers the best opportunity for invention and innovation. A well-recognized chemist and polymer expert, DeSimone has uniquely applied his skills to the development of groundbreaking solutions in green manufacturing, and promising applications in gene therapy and drug delivery, as well as medical devices. For his pioneering inventions, lab-to-marketplace entrepreneurship and commitment to mentorship, DeSimone has been awarded this year’s $500,000 Lemelson-MIT Prize.
DeSimone, Chancellor’s Eminent Professor of Chemistry at the University of North Carolina at Chapel Hill and William R. Kenan, Jr. Distinguished Professor of Chemical Engineering at North Carolina State University, will accept his award and present his accomplishments to the public at the Massachusetts Institute of Technology during the second-annual EurekaFest, a multi-day celebration of the inventive spirit, June 25-28, presented by the Lemelson-MIT Program. Creating Connections through Polymers “DuPont has licensed DeSimone’s breakthrough fluoropolymer-creation process, and we have built commercial facilities based on the technology, leading to unique products and more environmentally sustainable manufacturing,” said Nandan S. Rao, Global Technology Director, DuPont Fluoroproducts. “His ideas are truly revolutionary and represent dramatic departures from what others have pursued.” DeSimone has also crossed polymers with the field of medical devices. He collaborated with a research team led by Dr. Richard Stack, Professor Emeritus in Cardiology at Duke University and president of Synecor LLC, in developing technology for a fully bioabsorbable, polymer-based stent to provide an alternative to metallic stents. Bioabsorbable drug-coated stents promise to eliminate the need for a permanent prosthetic, offering the potential to improve the long-term safety of coronary stents and save patients’ lives. Guidant, now part of Abbott, purchased the technology from Synecor LLC, which is now in an international clinical trial for the treatment of coronary artery disease. This stent is the first of its kind to enter clinical trials. In addition, DeSimone serves as director of the National Science Foundation's (NSF) Science and Technology Center (STC) for Environmentally Responsible Solvents and Processes in North Carolina. “Linking sustainable, green chemistry to new cancer therapies and imaging techniques is just one example of his innovative and entrepreneurial leadership that has forged new directions in science,” said NSF Director Arden L. Bement. DeSimone and his team are currently utilizing fabrication processes from the microelectronics industry to create nanocarriers in medicine. DeSimone’s PRINT® (Particle Replication in Non-wetting Templates) technology can, for the first time, manufacture highly customizable and controllable nanobiomaterials for the diagnosis and treatment of disease, with promising applications in biotechnology and pharmaceuticals. Understanding that invention needs to be brought out of the laboratory and into the market to have a societal impact, DeSimone helped form Liquidia Technologies to commercialize the PRINT technology. He is also the co-principal investigator for the Carolina Center for Cancer Nanotechnology Excellence, which concentrates on projects using PRINT in oncology and is part of the National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer. Innovation: Where Diversity and Creativity Meet # # # ABOUT THE LEMELSON-MIT PROGRAM
|
